Our News
All the latest company news, views and insight from the Beckley Psytech team.
Beckley Psytech bolsters pipeline of next-generation psychedelic medicines with research collaborati...
Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s) Broad collaboration with Lophora will further strengthen Beckley Psytech’s world class management and R&D team
Beckley Psytech to attend and present at 8th Annual LSX World Congress 2022
Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the ... Read More
Beckley Psytech announces dosing of first healthy volunteers in Phase 1 clinical trial assessing saf...
Study represents continued efforts to further understand the clinical and pharmacological potential of 5-MeO-DMT. BPL-003 is Beckley Psytech’s innovative dry powder intranasal formulation of 5-MeO-DMT using FDA approved intranasal delivery devices.... Read More
Beckley Psytech to present at 32nd Annual Oppenheimer Healthcare Conference
Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the ... Read More
Beckley Psytech publishes peer-reviewed paper on 5-MeO-DMT in Journal of Psychopharmacology
Literature review highlights need for further clinical exploration of 5-MeO-DMT
Beckley Psytech announces first cohort of psychotherapists have begun training for treatment resista...
Initiation of training represents key step to incorporate psychedelic-assisted psychotherapy to deliver potentially clinically meaningful improvements
Beckley Psytech applies for B Corporation status as part of its commitment to have a positive impact...
B Corporations represent a new kind of business philosophy to protect and develop the future of all stakeholders.
Beckley Psytech to attend 11th Annual LifeSci Partners Virtual Corporate Access Event
CEO to participate in a panel discussion on the topic of “Psychedelics: More Than Just a Trip” – January 5, 2022 at 10:00 am ET / 3:00 pm GMT
Enhancing the accessibility of psychedelic healthcare
‘The combination of the drug and psychotherapy is critical. What will be interesting to see is how the healthcare infrastructure reacts to that. That will vary around the world because different healthcare systems are set up differently and mental ... Read More